

Sales Reconciliations  
Third Quarter 2014

	<u>Worldwide</u>	<u>U.S.</u>	<u>International</u>
Worldwide Operational Sales Growth	5.8%	11.6%	1.0%
Ex. Ortho-Clinical Diagnostics Divestiture	2.6%	3.2%	2.1%
<b>Adjusted Worldwide Operational Sales Growth</b>	<b>8.4%</b>	<b>14.8%</b>	<b>3.1%</b>
Consumer Operational Sales Growth	0.3%	-4.2%	
Ex. U.S. Women's Health*	1.9%	5.6%	
<b>Adjusted Operational Sales Growth</b>	<b>2.2%</b>	<b>1.4%</b>	
Pharmaceutical Operational Sales Growth	18.7%	33.1%	4.1%
Ex. Hepatitis C Products**	-10.7%	-18.9%	-2.5%
<b>Adjusted Operational Sales Growth</b>	<b>8.0%</b>	<b>14.2%</b>	<b>1.6%</b>
Medical Devices and Diagnostics Operational Sales Growth	-4.6%	-6.5%	-2.8%
Ex. Ortho-Clinical Diagnostics Divestiture	6.2%	7.1%	5.2%
<b>Adjusted Operational Sales Growth</b>	<b>1.6%</b>	<b>0.6%</b>	<b>2.4%</b>

\*Reflects the divestiture of the North American sanitary protection business

\*\*Hepatitis C products are OLYSIO®/SOVRIAD® and INCIVO®